Cargando…
P1521: IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT
Autores principales: | Salmanton-García, Jon, Marchesi, Francesco, Glenthøj, Andreas, Bilgin, Yavuz M., Praet, Jens VAN, Dávila-Valls, Julio, Martín-Pérez, Sonia, Labrador, Jorge, Van Doesum, Jaap, Falces-Romero, Iker, Farina, Francesca, Schönlein, Martin, Besson, Caroline, Petzer, Verena, Espigado, Ildefonso, Dargenio, Michelina, Aujayeb, Avinash, Sili, Uluhan, Serrano, Laura, Pinczes, Laszlo Imre, de Jonge, Nick, Soto-Silva, Andrés, Buquicchio, Caterina, Prezioso, Lucia, Marchetti, Monia, Meers, Stef, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Koehler, Philipp, Rahimli, Laman, Melis Çolak, Gökçe, Arellano, Elena, Wolf, Dominik, Gräfe, Stefanie, Ammatuna, Emanuele, Venemyr, Caroline Berg, Cornely, Oliver A., Pagano, Livio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430015/ http://dx.doi.org/10.1097/01.HS9.0000972964.65137.d1 |
Ejemplares similares
-
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report
por: Salmanton-García, Jon, et al.
Publicado: (2022) -
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
por: Pagano, Livio, et al.
Publicado: (2022) -
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
por: Marchesi, Francesco, et al.
Publicado: (2023) -
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
por: Busca, Alessandro, et al.
Publicado: (2023) -
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
por: Cattaneo, Chiara, et al.
Publicado: (2022)